

CANCER PREVENTION RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS FROM THE LITERATURE

- 379** **Editors' Selections from Relevant Scientific Publications**

SPOTLIGHT

- 381** **Evidence-Based Lung Cancer Screening in a Tailored Package**
Abbie Begnaud and Frank G. Ondrey
See related article, p. 423

RESEARCH ARTICLES

- 383** **Prediagnostic Serum Immune Marker Levels and Multiple Myeloma: A Prospective Longitudinal Study Using Samples from the Janus Serum Bank in Norway**
Simona Herdenberg, Carl Wibom, Esmeralda J.M. Krop, Hilde Langseth, Roel Vermeulen, Sophia Harlid, Wendy Yi-Ying Wu, and Florentin Späth
This study observed a decline in TGF- α serum levels closer to multiple myeloma diagnosis, which may aid in predicting multiple myeloma progression and early detection, although validation in other longitudinal cohorts is needed.
- 393** **From Therapy to Cancer Prevention Using HRD Testing on Patients with High-grade Ovarian Cancer**
Maria Grazia Tibiletti, Ileana Carnevali, Sofia Facchi, Valeria Pensotti, Giorgio Formenti, Nora Sahnane, Laura Libera, Susanna Ronchi, Sara Volorio, Marco Alessandro Pierotti, Stefano La Rosa, and Fausto Sessa
Genomic instability status (HRD testing), which is essential for making therapy choices, is useful to identify inherited ovarian cancers. Identifying these families with high cancer risk is critical for implementing targeted cancer prevention strategies.


- 401** **Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program**
Brandy M. Heckman-Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard Hamman, Helen P. Hazuda, Edward Horton, Mary A. Hoskin, Marjorie Perloff, Anna Bowers, William C. Knowler, Leslie G. Ford, and Marinella Temprosa; for the DPP Research Group
This study examines both metformin and ILS intervention as primary cancer prevention interventions in people at high risk for type 2 diabetes.
- 413** **Cancer Incidence and Survival after Emergency Department Care in the U.S. Midwest: An Opportunity for Cancer Interception**
Mark E. Sherman, Michael G. Heckman, Christopher C. DeStephano, Launia J. White, Jennifer L. St. Sauver, and Ruth M. Pfeiffer
This cohort analysis shows that cancer incidence over 6 years was lower among participants after an ED visit than among matched non-ED participants, whereas cancer-specific mortality was higher in the ED group ($HR_{\text{Adjusted}} = 1.76$; 95% CI, 1.49–2.08; $P = 3.62 \times 10^{-11}$), suggesting the potential benefit of preventive interventions.
- 423** **Implementing a Tribally Engaged Lung Cancer Screening Pilot Program in Rural Oklahoma**
Zsolt Nagykalai, Mark Doescher, Dorothy A. Rhoades, Kathleen Dwyer, Ann Chou, and Michele Gibson
Our community-engaged, multicomponent, and multilevel pilot implementation study significantly improved lung cancer screening rates in a rural, tribal health system. A key feature of this pilot study was a centralized screening coordination service supported by a population screening registry. We believe that our study is replicable in other settings.
See related Spotlight, p. 381

TABLE OF CONTENTS

ABOUT THE COVER

Changes in the levels of blood immune markers can help predict multiple myeloma progression. In the nested case-control study starting on page 383, Herdenberg and colleagues investigated the associations between the pre-diagnostic serum levels of candidate biomarkers and future multiple myeloma risk, as well as marker changes over time. The cover image, adapted from Supplementary Fig. S1, shows sample collection time for cases before multiple myeloma diagnosis. Interestingly, samples were collected up to 42 years before multiple myeloma diagnosis. The colors distinguish between first and additional sample collected. In this study, TGF- α levels decreased significantly closer to the diagnosis in multiple myeloma patients which warrants further investigation. The decrease in TGF- α levels may reflect subtle microenvironmental changes related to multiple myeloma progression.

doi: 10.1158/1940-6207.CAPR-18-7-CVR



NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to <https://aacrjournals.org/pages/editorial-policies#coi>.